Patient characteristics
| Patient no. . | Sex . | Age . | Indication . | Conditioning . | Donor . | Prophylaxis . | Stage . | CMV . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 4958 | M | 60 | Plasma cell leukemia | BCNU/Flu/ATG | URD | CSA/MMF | 3 | −/− | Death |
| 4975 | F | 20 | AML | Thio/Flu/ATG | Haplo | Treg | 2 | +/− | Death |
| 5026 | M | 68 | MDS | BCNU/Melph/Flu | URD | CSA/MTX | 2 | −/+ | Death |
| 5072 | F | 46 | Extranodal NKT | BCNU/VP-16/Cy | MRD | FK/PSE | 3 | −/+ | Death |
| 5112 | F | 41 | CML blast crisis | Bu/Cy | URD-1 | FK/MTX | 3 | +/− | Death |
| 5216 | F | 43 | AML | TBI/VP-16/CY | MRD | Treg | 2 | −/+* | Death |
| 5236 | M | 62 | MDS/MPN | BCNU/Melph/Flu | URD | FK/MMF | 2 | −/+† | IR |
| 4986 | M | 55 | MDS | Bu/Cy | URD | FK/MTX | 2 | +/+† | CR |
| 4998 | M | 53 | NHL | BCNU/VP-16/Cy | MRD | FK/PSE | 2 | −/− | CR |
| 5005 | F | 55 | CLL | TLI/ATG | URD-1 | CSA/MMF | 2 | −/+ | No steroids, CR |
| 5182 | F | 60 | Per. T-cell lymphoma | Bu/Cy | URD | FK/MTX | 2 | −/− | CR |
| 5199 | M | 39 | CML blast crisis | TBI/Cy | URD | FK/MTX | 2 | −/+* | CR |
| 5215 | M | 66 | CLL | TLI/ATG | URD | CSA/MMF | 3 | −/− | CR |
| 5261 | M | 53 | ALL | TBI/Cy | URD | FK/MTX | 3 | −/− | CR |
| 5314 | F | 38 | ALL | TBI/VP-16/Cy | URN-1 | FK/MTX | 2 | +/+ | CR |
| Patient no. . | Sex . | Age . | Indication . | Conditioning . | Donor . | Prophylaxis . | Stage . | CMV . | Outcome . |
|---|---|---|---|---|---|---|---|---|---|
| 4958 | M | 60 | Plasma cell leukemia | BCNU/Flu/ATG | URD | CSA/MMF | 3 | −/− | Death |
| 4975 | F | 20 | AML | Thio/Flu/ATG | Haplo | Treg | 2 | +/− | Death |
| 5026 | M | 68 | MDS | BCNU/Melph/Flu | URD | CSA/MTX | 2 | −/+ | Death |
| 5072 | F | 46 | Extranodal NKT | BCNU/VP-16/Cy | MRD | FK/PSE | 3 | −/+ | Death |
| 5112 | F | 41 | CML blast crisis | Bu/Cy | URD-1 | FK/MTX | 3 | +/− | Death |
| 5216 | F | 43 | AML | TBI/VP-16/CY | MRD | Treg | 2 | −/+* | Death |
| 5236 | M | 62 | MDS/MPN | BCNU/Melph/Flu | URD | FK/MMF | 2 | −/+† | IR |
| 4986 | M | 55 | MDS | Bu/Cy | URD | FK/MTX | 2 | +/+† | CR |
| 4998 | M | 53 | NHL | BCNU/VP-16/Cy | MRD | FK/PSE | 2 | −/− | CR |
| 5005 | F | 55 | CLL | TLI/ATG | URD-1 | CSA/MMF | 2 | −/+ | No steroids, CR |
| 5182 | F | 60 | Per. T-cell lymphoma | Bu/Cy | URD | FK/MTX | 2 | −/− | CR |
| 5199 | M | 39 | CML blast crisis | TBI/Cy | URD | FK/MTX | 2 | −/+* | CR |
| 5215 | M | 66 | CLL | TLI/ATG | URD | CSA/MMF | 3 | −/− | CR |
| 5261 | M | 53 | ALL | TBI/Cy | URD | FK/MTX | 3 | −/− | CR |
| 5314 | F | 38 | ALL | TBI/VP-16/Cy | URN-1 | FK/MTX | 2 | +/+ | CR |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CR, complete response; CSA, cyclosporine; FK, tacrolimus; Haplo, haploidentical donor; MDS, myelodysplastic syndrome; MMF, mycophenylate mofetil; MPN, myeloproliferative neoplasm; MRD, matched related donor; MTX, methotrexate; NHL, non-Hodgkins lymphoma; IR, incomplete response; PSE, prednisone; URD, unrelated donor; URD-1, unrelated donor with 1 mismatch.
Underlined patients are SR; all others are PR.
CMV PCR tissue positivity <150 copies, shell vial, and culture negative.
CMV PCR blood positivity.